HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened

• Heron Therapeutics, Inc. (ticker: HRTX) filed an 8-K on June 25, 2026 reporting that Nasdaq’s Listing Qualifications Department sent a notice that the company’s closing bid price was below the $1.00 minimum for 30 consecutive trading days (May 12, 2026 – June 24, 2026). Nasdaq has given Heron 180 calendar days, until December 22, 2026, to cure the deficiency and regain compliance. There is no immediate change to the listing or trading of HRTX shares.

Key Details

• Closing bid price was under Nasdaq’s $1.00 minimum for 30 consecutive trading days (May 12–June 24, 2026).
• Initial compliance period: 180 days (deadline Dec 22, 2026); compliance can be achieved if the closing bid is ≥ $1.00 for at least 10 consecutive trading days (Nasdaq may require up to ~20 business days).
• If not cured, the company may be eligible for a second 180-day period only if it meets market value and other initial listing standards (except the bid price) and notifies Nasdaq — a reverse stock split may be required.
• Trading continues on The Nasdaq Capital Market under symbol “HRTX”; delisting would only occur after further Nasdaq notification and possible appeal.

Why It Matters

• For investors, this notice signals a material listing risk tied directly to the company’s share price: failure to regain the $1.00 closing bid could lead to delisting, reduced liquidity, and potential downward pressure on share value. The filing confirms there is no immediate trading halt, but the outcome depends on share-price performance and any corrective actions (such as a reverse split) Heron may take. The company’s future listing status and investor liquidity will hinge on meeting Nasdaq’s timelines and requirements.